Using expression data of gene, miRNA, and protein from 150 breast cancer samples available at TCGA (Table 2),24 DIABLO was showcased to identify multi-omics signatures (putative biomarkers) that could distinguish the breast cancer subtypes, namely, Basal, HER2, and Luminal A.51 Thus, mixOmics can address both disease subtyping and biomarker prediction. Here, ERBB2 is linked to breast carcinoma.